The evolution of drug-resistant malaria: the role of drug elimination half-life.

This paper seeks to define and quantify the influence of drug elimination half-life on the evolution of antimalarial drug resistance. There are assumed to be three general classes of susceptibility of the malaria parasite Plasmodium falciparum to a drug: Res0, the original, susceptible wildtype; Res1, a group of intermediate levels of susceptibility that are more tolerant of the drug but still cleared by treatment; and Res2, which is completely resistant to the drug. Res1 and Res2 resistance both evolve much faster if the antimalarial drug has a long half-life. We show that previous models have significantly underestimated the rate of evolution of Res2 resistance by omitting the effects of drug half-life. The methodology has been extended to investigate (i) the effects of using drugs in combination, particularly when the components have differing half-lives, and (ii) the specific example of the development of resistance to the antimalarial pyrimethamine-sulphadoxine. An important detail of the model is the development of drug resistance in two separate phases. In phase A, Res1 is spreading and replacing the original sensitive forms while Res2 remains at a low level. Phase B starts once parasites are selected that can escape drug action (Res1 genotypes with borderline chemosensitivity, and Res2): these parasites are rapidly selected, a process that leads to widespread clinical failure. Drug treatment is clinically successful during phase A, and health workers may be unaware of the substantial changes in parasite population genetic structure that predicate the onset of phase B. Surveillance programs are essential, following the introduction of a new drug, to monitor effectively changes in treatment efficacy and thus provide advance warning of drug failure. The model is also applicable to the evolution of antibiotic resistance in bacteria: in particular, the need for these models to incorporate drug pharmacokinetics to avoid potentially large errors in their predictions.

[1]  W. Peters,et al.  Chemotherapy and drug resistance in malaria. , 1970 .

[2]  D. Hartl,et al.  Principles of population genetics , 1981 .

[3]  D. Falconer Introduction to quantitative genetics. 1. ed. , 1984 .

[4]  C. Curtis,et al.  A simple model of the build-up of resistance to mixtures of anti-malarial drugs. , 1986, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[5]  R. Howells,et al.  A preliminary pharmacokinetic study of the antimalarial drugs, proguanil and chlorproguanil , 1987, The Journal of pharmacy and pharmacology.

[6]  T. Hughes,et al.  The population dynamics of reef fishes , 1988 .

[7]  A. Breckenridge,et al.  Inter-subject variability in the metabolism of proguanil to the active metabolite cycloguanil in man. , 1989, British journal of clinical pharmacology.

[8]  A. Breckenridge,et al.  Variability in the metabolism of proguanil to the active metabolite cycloguanil in healthy Kenyan adults. , 1990, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[9]  W. Peters,et al.  The prevention of antimalarial drug resistance. , 1990, Pharmacology & therapeutics.

[10]  B. Singer,et al.  Modelling the development of resistance of Plasmodium falciparum to anti-malarial drugs. , 1991, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[11]  C. Curtis,et al.  Trial of pyrethroid impregnated bednets in an area of Tanzania holoendemic for malaria. Part 4. Effects on incidence of malaria infection. , 1991, Acta tropica.

[12]  S. Ward,et al.  Inter-individual variation in the metabolic activation of the antimalarial biguanides. , 1991, Parasitology today.

[13]  W. Watkins,et al.  Treatment of Plasmodium falciparum malaria with pyrimethamine-sulfadoxine: selective pressure for resistance is a function of long elimination half-life. , 1993, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[14]  R. Price,et al.  Artesunate versus artemether in combination with mefloquine for the treatment of multidrug-resistant falciparum malaria. , 1995, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[15]  P. Olliaro,et al.  Strategies for the prevention of antimalarial drug resistance: rationale for combination chemotherapy for malaria. , 1996, Parasitology today.

[16]  D. Kyle,et al.  Comparative bioavailability of oral, rectal, and intramuscular artemether in healthy subjects: use of simultaneous measurement by high performance liquid chromatography and bioassay. , 1996, British journal of clinical pharmacology.

[17]  R. Frankham Introduction to quantitative genetics (4th edn): by Douglas S. Falconer and Trudy F.C. Mackay Longman, 1996. £24.99 pbk (xv and 464 pages) ISBN 0582 24302 5 , 1996 .

[18]  I. Hastings,et al.  A model for the origins and spread of drug-resistant malaria , 1997, Parasitology.

[19]  O. Doumbo,et al.  Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance. , 1997, The Journal of infectious diseases.

[20]  J. E. Hyde,et al.  Resistance to antifolates in Plasmodium falciparum monitored by sequence analysis of dihydropteroate synthetase and dihydrofolate reductase alleles in a large number of field samples of diverse origins. , 1997, Molecular and biochemical parasitology.

[21]  C. Curtis,et al.  Resistance to pyrimethamine/sulfadoxine in Plasmodium falciparum in 12 villages in north east Tanzania and a test of chlorproguanil/dapsone. , 1997, Acta tropica.

[22]  C. Plowe,et al.  The efficacy of antifolate antimalarial combinations in Africa: a predictive model based on pharmacodynamic and pharmacokinetic analyses. , 1997, Parasitology today.

[23]  B. Levin,et al.  The population dynamics of antimicrobial chemotherapy , 1997, Antimicrobial agents and chemotherapy.

[24]  B G Williams,et al.  Multigenic drug resistance among inbred malaria parasites , 1997, Proceedings of the Royal Society of London. Series B: Biological Sciences.

[25]  E. Lagarde,et al.  Impact of chloroquine resistance on malaria mortality. , 1998, Comptes rendus de l'Academie des sciences. Serie III, Sciences de la vie.

[26]  D. Arnot,et al.  Unstable malaria in Sudan: the influence of the dry season. Clone multiplicity of Plasmodium falciparum infections in individuals exposed to variable levels of disease transmission. , 1998, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[27]  N. White,et al.  Preventing antimalarial drug resistance through combinations. , 1998, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[28]  C. Plowe,et al.  Kenyan Plasmodium falciparum Field Isolates: Correlation between Pyrimethamine and Chlorcycloguanil Activity In Vitro and Point Mutations in the Dihydrofolate Reductase Domain , 1998, Antimicrobial Agents and Chemotherapy.

[29]  J. Koella Costs and benefits of resistance against antimalarial drugs. , 1998, Parasitology today.

[30]  R. Anderson,et al.  The dynamics of drug action on the within-host population growth of infectious agents: melding pharmacokinetics with pathogen population dynamics. , 1998, Journal of theoretical biology.

[31]  C. Goodman,et al.  Cost-effectiveness of malaria control in sub-Saharan Africa , 1999, The Lancet.

[32]  R. Snow,et al.  Averting a malaria disaster , 1999, The Lancet.

[33]  R. Snow,et al.  Estimating mortality, morbidity and disability due to malaria among Africa's non-pregnant population. , 1999, Bulletin of the World Health Organization.

[34]  N. White,et al.  Antimalarial drug resistance and combination chemotherapy. , 1999, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[35]  E. Nduati,et al.  Molecular evidence of greater selective pressure for drug resistance exerted by the long-acting antifolate Pyrimethamine/Sulfadoxine compared with the shorter-acting chlorproguanil/dapsone on Kenyan Plasmodium falciparum. , 2000, The Journal of infectious diseases.

[36]  P. Winstanley Chemotherapy for falciparum malaria: the armoury, the problems and the prospects. , 2000, Parasitology today.

[37]  J. Trape,et al.  Gametocytemia and infectivity to mosquitoes of patients with uncomplicated Plasmodium falciparum malaria attacks treated with chloroquine or sulfadoxine plus pyrimethamine. , 2000, The American journal of tropical medicine and hygiene.

[38]  A. Nzila,et al.  Towards an Understanding of the Mechanism of Pyrimethamine-Sulfadoxine Resistance in Plasmodium falciparum: Genotyping of Dihydrofolate Reductase and Dihydropteroate Synthase of Kenyan Parasites , 2000, Antimicrobial Agents and Chemotherapy.

[39]  A. Nzila,et al.  The changing in vitro susceptibility pattern to pyrimethamine/sulfadoxine in Plasmodium falciparum field isolates from Kilifi, Kenya. , 2000, The American journal of tropical medicine and hygiene.

[40]  U. d’Alessandro,et al.  Modelling a predictable disaster: the rise and spread of drug-resistantmalaria. , 2000, Parasitology today.

[41]  I. Goldman,et al.  Resistance to antifolates , 2003, Oncogene.